Metrorrhagia (Intermenstrual Bleeding): Causes, Risks, and Treatment

What is Metrorrhagia?

Metrorrhagia is the abundant and prolonged uterine bleeding occurring unexpectedly between two consecutive menstrual periods. It is also referred to as intermenstrual bleeding (IMB) in clinical practice.

The key defining feature of metrorrhagia is that it is:

• Unexpected: it occurs outside the anticipated window of menstruation
• Significant: it is more than just minor spotting
• Uterine in origin: it comes from the uterus, not from other parts of the genital tract (though distinguishing this clinically sometimes requires examination)

How Does Metrorrhagia Differ from Related Conditions?

It is important to distinguish metrorrhagia from two related but clinically distinct conditions:

• Spotting: An atypical, irregular uterine bleed occurring between periods, but characterized by minimal blood loss (typically just a few drops or a light stain, insufficient to require a sanitary pad). Spotting is often a normal occurrence around the time of ovulation and can also be an early sign of pregnancy.

• Menorrhagia: Heavy and/or prolonged bleeding occurring during the menstrual period itself, i.e., at the expected time of menstruation but exceeding normal parameters of volume (over 80 mL per cycle) or duration (over 7 days). Menorrhagia represents an abnormality of the menstrual period itself, whereas metrorrhagia represents bleeding that occurs entirely outside of it.

In some women, these patterns can overlap. For instance, a woman may experience both heavy periods (menorrhagia) and bleeding between periods (metrorrhagia) at the same time. This combination is sometimes described as menometrorrhagia.

Should Metrorrhagia Always Be Investigated?

In most cases, intermenstrual bleeding has a benign, non-dangerous cause. However, because it can occasionally signal a serious underlying condition, such as cancer of the uterus or cervix, it should always be evaluated by a gynecologist, no matter how mild it may appear.

This is especially true for:

• Postmenopausal women: Any uterine bleeding after menopause must be considered a potential sign of endometrial cancer until proven otherwise and requires urgent gynecological assessment.
• Pregnant women: Bleeding during pregnancy has specific and distinct causes and management. For pregnancy-related bleeding, please refer to our dedicated article on pregnancy-related vaginal discharge and bleeding.
• Women with recurring intermenstrual bleeding: Even if a single episode proves to be benign, recurrent intermenstrual bleeding always merits investigation.

---

Causes of Metrorrhagia

While light midcycle spotting can be physiologically associated with the hormonal fluctuations that occur around ovulation in some women, more significant intermenstrual bleeding generally indicates a pathological process. The word “pathological” in this context doesn’t always mean serious or dangerous. In fact, many of the causes listed below are entirely benign and easily treated.

The main causes of metrorrhagia are described in detail below.

1. Hormonal Contraceptives

Hormonal contraception is one of the most common causes of intermenstrual bleeding, particularly in women who have recently started a new method or changed their regimen.

The following hormonal contraceptive methods are all associated with a risk of intermenstrual bleeding, particularly during the first 3–6 months of use:

• Combined oral contraceptive pill (COCP): The most widely used form of hormonal contraception. Breakthrough bleeding (bleeding that occurs while the pill is being taken, outside of the pill-free week) is a recognized side effect, especially when:
  • Pills are started for the first time
  • Pills are missed or taken at inconsistent times
  • A woman switches from one formulation to another
  • Certain medications (e.g., rifampicin, some anticonvulsants) interact with the pill’s efficacy
• Contraceptive patch: Similar breakthrough bleeding patterns as the COCP
• Vaginal ring (NuvaRing): Also associated with breakthrough bleeding, particularly during the first cycle of use
• Intrauterine device (IUD/coil): Both the hormonal (levonorgestrel-releasing, LNG-IUS) and non-hormonal (copper IUD) coils can cause irregular bleeding, particularly in the first 3–6 months after insertion. The copper IUD tends to increase menstrual bleeding and may cause intermenstrual spotting; the hormonal IUD typically reduces overall bleeding but may initially cause irregular spotting until the endometrium adjusts.
• Progestogen-only pill (mini-pill): Irregular and unpredictable bleeding is a common side effect, as this method suppresses ovulation inconsistently and does not produce a regular withdrawal bleed.
• Subdermal implants (e.g., Nexplanon): Highly effective at preventing pregnancy but frequently associated with irregular bleeding patterns.

In most cases, contraceptive-related breakthrough bleeding resolves spontaneously within 3–6 months. If it persists, a gynecologist may recommend adjusting the contraceptive formulation or switching to an alternative method.

2. Pelvic Infections

Pelvic infections, such as infections of the uterus (endometritis), fallopian tubes (salpingitis), and cervix (cervicitis), are a significant cause of intermenstrual bleeding. This is especially true in the following cases:

• Sexually active women of reproductive age
• Women who have recently given birth
• Women who have recently undergone uterine or cervical surgery or procedures (including termination of pregnancy, intrauterine device insertion, hysteroscopy)

The most common sexually transmitted pathogens responsible include:

• Chlamydia trachomatis: The most frequently identified STI associated with cervicitis and pelvic inflammatory disease (PID) in young women; often asymptomatic, making it easy to miss without testing
• Neisseria gonorrhoeae: Can cause cervicitis, endometritis, and PID; intermenstrual bleeding is a recognized presentation
• Trichomonas vaginalis: A vaginal infection that can cause contact bleeding from cervical or vaginal inflammation
• Bacterial vaginosis (BV): An overgrowth of anaerobic bacteria in the vaginal flora; can cause an inflamed, fragile cervix that bleeds easily

Associated symptoms that accompany infection-related metrorrhagia often include:

• Pelvic pain, especially during or after sex (also known as dyspareunia)
• Abnormal or malodorous vaginal discharge
• Fever (in more severe cases of PID)
• Pain during urination (dysuria)
• Lower abdominal tenderness

Prompt treatment of pelvic infections with appropriate antibiotics is essential. This helps prevent complications such as chronic pelvic pain, fallopian tube damage, and infertility.

3. Post-Caesarean Section Bleeding (Caesarean Scar Defect / Isthmocele)

A proportion of women who have undergone one or more caesarean sections may develop a uterine scar defect. This condition, also known as a caesarean scar defect or isthmocele, is a niche or indentation in the lower segment of the uterus at the site of the surgical incision.

This structural defect can accumulate menstrual blood and discharge. The trapped fluid is then released in the days immediately after the main menstrual flow has ended, creating a characteristic pattern of postmenstrual spotting or intermenstrual bleeding that typically begins shortly after the period ends.

The risk of developing a significant scar defect increases with the number of previous caesarean deliveries. Symptoms may include:

• Intermenstrual spotting or bleeding (characteristically starting at the end of the period)
• Pelvic pain
• Dysmenorrhea
• Rarely, fertility issues

Management ranges from expectant observation in mild cases to surgical correction (hysteroscopic or laparoscopic repair of the scar defect) in women with significant symptoms or fertility concerns.

4. Uterine and Cervical Polyps

A polyp is a localized overgrowth of cells on a small vascular stalk, forming a soft, fleshy protrusion. Polyps can develop either inside the uterine cavity (endometrial/uterine polyps) or on the cervix (cervical polyps).

Uterine polyps:

• Develop from the endometrium (the inner lining of the uterus).
• More common in women in their 40s and 50s, and in women using tamoxifen.
• Often cause intermenstrual bleeding, heavy periods, or postmenopausal bleeding.
• Usually benign, these polyps may, in a small percentage of cases, contain precancerous or cancerous cells. This risk is especially notable in postmenopausal women.
• Diagnosed by transvaginal ultrasound or hysteroscopy.
• Treated by hysteroscopic polypectomy (surgical removal during hysteroscopy).

Cervical polyps:

• Develop from the endocervical (inner cervical) mucosa.
• Often asymptomatic but can cause intermenstrual bleeding or postcoital bleeding (bleeding after sexual intercourse).
• Usually benign; very rarely malignant.
• Diagnosed on speculum examination.
• Removed by simple twisting or avulsion in clinic. This is usually quick, simple, and well tolerated.

5. Uterine Fibroids (Leiomyomas)

While uterine fibroids are more commonly linked to heavy menstrual periods (menorrhagia), submucosal fibroids, which project into the uterine cavity, can also cause intermenstrual bleeding. This occurs because they disrupt the endometrial surface and interfere with the normal mechanisms that control bleeding.

Fibroids are benign smooth muscle tumors of the uterus, extremely common (affecting up to 70–80% of women by age 50), and rarely malignant. Their management depends on size, location, symptom burden, and the woman’s reproductive plans.

6. Cancer and Precancerous Lesions

While far less common than the benign causes listed above, malignant or precancerous conditions of the reproductive tract must always be considered in the differential diagnosis of metrorrhagia:

• Endometrial cancer (uterine cancer): The most common gynecological malignancy in women in high-income countries. Abnormal uterine bleeding is the cardinal symptom. This includes intermenstrual bleeding and, most notably, postmenopausal bleeding. Risk factors include obesity, diabetes, hypertension, late menopause, nulliparity (never having given birth), unopposed estrogen therapy, tamoxifen use, PCOS, and family history (including Lynch syndrome).
• Cervical cancer: Caused in the vast majority of cases by persistent infection with high-risk strains of human papillomavirus (HPV). Intermenstrual bleeding and postcoital bleeding are classic presenting symptoms. Cervical cancer is highly unlikely in women who have been vaccinated against HPV and who attend regular cervical screening (Pap smear/HPV test). Risk factors include multiple sexual partners, early sexual debut, smoking, and immunosuppression.
• Endometrial hyperplasia: An abnormal thickening of the uterine lining due to excessive estrogen stimulation without adequate progesterone opposition; not yet cancer, but a precancerous condition that can progress to endometrial cancer if untreated.

Any woman with postmenopausal bleeding must be assessed urgently to exclude endometrial cancer. Similarly, persistent intermenstrual bleeding in women of any age, particularly when it occurs with postcoital bleeding, unusual vaginal discharge, or weight loss, requires thorough investigation.

7. Coagulation Disorders

Bleeding disorders, both inherited and acquired, are an underrecognized cause of abnormal uterine bleeding in women. They affect the blood’s ability to clot normally, leading to prolonged or heavy bleeding that may manifest as menorrhagia, metrorrhagia, or both.

The most important include:

• Von Willebrand disease (VWD): The most common inherited bleeding disorder, caused by a deficiency or dysfunction of von Willebrand factor. This protein is essential for platelet adhesion. Many women with VWD are not diagnosed until they present with heavy or prolonged menstrual bleeding, often from menarche onwards. VWD affects approximately 1% of the population.
• Platelet disorders: Including immune thrombocytopenic purpura (ITP) and inherited platelet function defects
• Factor deficiencies: Including mild hemophilia A or B in carrier females
• Acquired coagulopathies: Including those caused by liver disease, vitamin K deficiency, or anticoagulant medications

Assessment for a coagulation disorder should be considered particularly in:

• Women with a lifelong history of heavy menstrual bleeding starting from their first period (menarche)
• Women with a personal or family history of easy bruising, nosebleeds, or prolonged bleeding after minor cuts or surgery
• Adolescents with severe intermenstrual or menstrual bleeding

8. Medications

Several commonly used medications can cause or contribute to metrorrhagia:

• Emergency contraception: Both the levonorgestrel pill (morning-after pill) and the ulipristal acetate pill (5-day pill) frequently cause intermenstrual bleeding or changes in the timing and heaviness of the next menstrual period. This is an expected and recognized effect, not a sign of treatment failure.
• Aspirin and antiplatelet drugs: By inhibiting platelet aggregation, these drugs impair normal hemostasis and can worsen uterine bleeding.
• Anticoagulants: These include warfarin, heparin, and direct oral anticoagulants (DOACs) such as rivaroxaban, apixaban, and dabigatran. All of these medications increase bleeding risk.
• Tamoxifen: Used in breast cancer treatment; has estrogenic effects on the uterus that can cause endometrial thickening, polyps, and abnormal bleeding.
• Antipsychotics and some antidepressants: Can elevate prolactin levels (hyperprolactinemia), disrupting normal ovulation and menstrual regularity.

9. Pregnancy-Related Causes

If there is any possibility of pregnancy, several obstetric causes of intermenstrual bleeding must be considered:

• Implantation bleeding: Light spotting that can occur when the fertilized embryo implants in the uterine lining, approximately 6–12 days after conception. Often confused with an early or light period.
• Ectopic pregnancy: A potentially life-threatening condition where a fertilized egg implants outside the uterus, typically in a fallopian tube. Vaginal bleeding combined with unilateral pelvic pain in early pregnancy is a classic presentation requiring immediate medical assessment.
• Threatened miscarriage: Bleeding in early pregnancy with a viable intrauterine pregnancy still detectable on ultrasound.
• Spontaneous miscarriage: Pregnancy loss before 24 weeks of gestation, often preceded and accompanied by uterine bleeding.

A pregnancy test should always be performed as part of the initial workup for intermenstrual bleeding in any woman of reproductive age who is sexually active.

10. Dysfunctional Uterine Bleeding (No Identifiable Cause)

When no structural, infectious, hormonal, pharmacological, or malignant cause can be identified after a thorough investigation, the bleeding is sometimes described as “dysfunctional uterine bleeding”. This term is now being gradually replaced in modern gynecological nomenclature by the more precise terminology of abnormal uterine bleeding (AUB), which includes specific subcategories.

Anovulatory Cycle

One of the most clinically important and frequently overlooked causes of metrorrhagia is the anovulatory cycle. This is a menstrual cycle in which the ovaries fail to release a mature egg, meaning ovulation does not occur.

It is estimated that anovulatory cycles account for approximately 90% of dysfunctional uterine bleeding and are particularly prevalent at the two extremes of reproductive life:

• Puberty/adolescence: In the first few years after menarche (the onset of menstruation), the hypothalamic-pituitary-ovarian axis is still maturing, and anovulatory cycles are extremely common.
• Perimenopause: In the years leading up to menopause, declining ovarian reserve and fluctuating hormone levels result in increasingly frequent anovulatory cycles.

The Mechanism of Anovulatory Bleeding

In a normal ovulatory menstrual cycle:

1. Estrogen stimulates the endometrium to thicken during the follicular phase (the first half of the cycle).
2. Ovulation occurs, and the ruptured follicle transforms into the corpus luteum. This temporary glandular structure produces progesterone.
3. Progesterone stabilizes and matures the endometrium, preparing it for potential embryo implantation.
4. If implantation does not occur, the corpus luteum degenerates, progesterone and estrogen levels drop, and a predictable, well-organized menstrual bleed occurs.

In an anovulatory cycle:

• Without ovulation, the corpus luteum does not form.
• Therefore, no progesterone is produced during the second half of the cycle.
• Estrogen continues to stimulate endometrial proliferation unopposed by progesterone.
• The endometrium grows increasingly thick and unstable.
• Eventually, the estrogen level fluctuates enough to cause parts of the poorly supported endometrium to break down and bleed. However, the bleeding is irregular, unpredictable, and often heavy, since there is no organized progesterone-mediated shedding.
• This is the mechanism behind anovulatory intermenstrual bleeding (metrorrhagia).

Causes of Anovulatory Cycles

A wide range of factors can disrupt normal ovulation:

• Psychological stress: Severe or chronic stress activates the hypothalamic-pituitary-adrenal (HPA) axis. This, in turn, suppresses the hypothalamic-pituitary-ovarian (HPO) axis and inhibits GnRH pulsatility, the hormonal signal necessary to trigger ovulation.
• Changes in body weight: Both obesity (which elevates estrogen through peripheral aromatization) and low body weight (anorexia nervosa or extreme thinness) disrupt the HPO axis and impair ovulation. Rapid weight changes in either direction can also trigger anovulation.
• Excessive exercise: Extremely high training loads, such as those experienced by elite athletes, can suppress ovulation. This happens through a combination of energy deficit, low body fat, and stress-related hormonal changes, known as the “female athlete triad”.
• Polycystic ovary syndrome (PCOS): The most common endocrine disorder of reproductive-age women; characterized by chronic anovulation, elevated androgens, and polycystic ovarian morphology on ultrasound.
• Thyroid disorders: Both hypothyroidism and hyperthyroidism disrupt the HPO axis and impair normal ovulatory function. Thyroid disease is a frequently overlooked cause of menstrual irregularity.
• Hyperprolactinemia: Elevated prolactin, which can result from a pituitary adenoma, thyroid disease, or certain medications, suppresses GnRH and inhibits ovulation.
• Perimenopause: Natural decline in ovarian reserve and fluctuating hormone levels lead to progressive failure of ovulatory function.
• Hypothalamic amenorrhea: A functional suppression of the HPO axis, often multifactorial (stress + energy deficit + excessive exercise).

For a more detailed discussion of this topic, please refer to our dedicated article: Anovulatory Cycle.

---

Complications

Metrorrhagia is a symptom, not a disease in itself. Beyond the complications specific to any underlying cause (which vary widely depending on the diagnosis), the most clinically important direct complication of recurrent or heavy intermenstrual bleeding is iron-deficiency anemia.

Iron-Deficiency Anemia

Repeated blood loss, whether from heavy menstrual periods, intermenstrual bleeding, or both, gradually depletes the body’s iron stores. It also reduces the number of circulating red blood cells and the hemoglobin available to carry oxygen. The resulting iron-deficiency anemia can cause a wide range of symptoms:

• Persistent fatigue and weakness.
• Pallor: paleness of the skin, conjunctivae, and mucous membranes.
• Chest pain or tightness.
• Palpitations: an awareness of a rapid or irregular heartbeat.
• Shortness of breath on exertion.
• Headaches.
• Dizziness and lightheadedness.
• Cold hands and cold feet.
• Glossitis: inflammation or soreness of the tongue.
• Brittle, spoon-shaped nails (koilonychia).
• Pica, an unusual craving for non-food substances like ice (pagophagia), chalk, or soil, is a characteristic but often overlooked sign of severe iron deficiency.

Iron-deficiency anemia is especially serious in women who are also pregnant (where it increases the risk of preterm birth and low birth weight), in adolescents (where it can affect growth and cognitive development), and in working-age women (where it significantly impairs productivity, concentration, and quality of life).

Impact on Quality of Life

Although not directly dangerous to physical health in milder forms, the persistent presence of unpredictable intermenstrual bleeding can significantly interfere with a woman’s daily life, including:

• Anxiety about unexpected bleeding episodes when away from home
• Social withdrawal and avoidance of activities (exercise, travel, work, intimate relationships)
• Embarrassment and loss of self-confidence
• Disrupted sleep
• Reduced work performance

This psychosocial dimension of metrorrhagia is frequently underestimated by healthcare providers and deserves to be acknowledged and addressed as part of comprehensive care.

---

Diagnosis

A correct and complete diagnosis of metrorrhagia begins with a thorough clinical assessment. No investigation can replace a careful history and physical examination. Additional tests are then selected based on what is clinically most likely given the individual patient’s profile.

Step 1: Medical History (Anamnesis)

The gynecologist will gather a detailed clinical history, including:

• Menstrual history: Age at menarche, usual cycle length and regularity, normal duration and volume of periods, date of last menstrual period
• Characteristics of the bleeding: When it started, how long it has been present, its volume and character, whether it is related to sexual intercourse (postcoital bleeding is a red flag for cervical pathology), whether it occurs at a predictable point in the cycle
• Obstetric history: Number of pregnancies, deliveries (including caesarean sections), miscarriages
• Contraceptive history: Current and past methods, any recent changes
• Medication history: NSAIDs, anticoagulants, antiplatelet agents, hormonal medications, tamoxifen, antipsychotics
• Gynecological history: Previous STIs, pelvic inflammatory disease, uterine or cervical surgery, abnormal smear results, known fibroids or polyps
• Family history: Gynecological cancers (particularly endometrial and ovarian), bleeding disorders, PCOS
• General health: Symptoms of thyroid disease, signs of significant weight change, psychological stress, exercise habits
• Review of systems: Weight loss, fatigue, pain, urinary symptoms, bowel changes (relevant for excluding malignancy)

Step 2: Physical Examination

The physical and pelvic examination includes:

• General assessment: BMI, pallor (suggesting anemia), signs of systemic disease (thyroid enlargement, acne/hirsutism suggesting androgen excess in PCOS).
• Speculum examination: This procedure allows direct visualization of the cervix and vaginal walls. It helps identify cervical polyps, signs of cervicitis, abnormal discharge, or visible cervical lesions.
• Bimanual (pelvic) examination: Assessment of uterine size, shape, tenderness, and mobility; evaluation of adnexal (ovarian and fallopian tube) areas for masses or tenderness.

Step 3: Laboratory Investigations

Blood tests are selected based on clinical suspicion:

• Hormonal profile:

  • LH (luteinizing hormone) and FSH (follicle-stimulating hormone): To assess ovarian function and distinguish anovulatory from ovulatory patterns
  • Estradiol and progesterone: To assess estrogenic status and confirm (or exclude) ovulation
  • Prolactin: To screen for hyperprolactinemia
  • TSH (thyroid-stimulating hormone): This test screens for thyroid dysfunction, which is often overlooked but can be easily treated. It is a common cause of menstrual irregularity.
  • Testosterone and DHEAS (dehydroepiandrosterone sulfate): If PCOS is suspected

• Iron studies:

  • Serum ferritin: The most sensitive marker of iron deficiency (depleted before hemoglobin falls).
  • Serum iron and total iron-binding capacity (TIBC).
  • Full blood count (FBC): To assess hemoglobin and mean corpuscular volume (MCV). A low MCV suggests iron-deficiency anemia.

• Coagulation screen: PT/INR, aPTT, and fibrinogen, particularly if a bleeding disorder is suspected.

• STI screening: Swabs for chlamydia and gonorrhea (cervical or self-collected vaginal), wet mount microscopy for trichomonas and bacterial vaginosis.

• Pregnancy test: A urine or serum beta-hCG test should be performed in all sexually active women of reproductive age presenting with abnormal uterine bleeding.

Step 4: Imaging

• Transvaginal ultrasound: The first-line imaging investigation for metrorrhagia. It allows detailed assessment of:

  • Uterine size, shape, and myometrial texture
  • Endometrial thickness and echo pattern (an excessively thick endometrium in a postmenopausal woman is a red flag for endometrial cancer).
  • Uterine fibroids vary in location, size, and number, and their proximity to the endometrial cavity also plays a key role.
  • Uterine polyps (may appear as focal intracavitary lesions; saline infusion sonography/SIS improves detection).
  • Ovarian morphology (polycystic appearance, follicle count, ovarian cysts).
  • Caesarean scar defect (isthmocele).

• CT scan: May be used for staging if malignancy is suspected or confirmed, or to evaluate the pelvis when ultrasound is inconclusive.

• MRI of the pelvis: Provides superior soft tissue detail; particularly valuable for:

  • Characterizing fibroids (including differentiating from adenomyosis)
  • Staging endometrial cancer
  • Evaluating deep pelvic pathology not clearly seen on ultrasound

Step 5: Additional Gynecological Investigations

• Pap smear (cervical cytology) and/or HPV test: These tests screen for cervical precancerous lesions and HPV infection. They are particularly important if intermenstrual bleeding occurs alongside postcoital bleeding.

• Endometrial biopsy (EMB): A small sample of the endometrial lining is obtained (usually using a narrow suction catheter in an outpatient setting without anesthesia) and sent for histological examination. Indicated in:

  • Postmenopausal women with any uterine bleeding
  • Women over 45 with persistent unexplained intermenstrual bleeding
  • Women under 45 with risk factors for endometrial cancer (obesity, PCOS, prolonged anovulation, family history)
  • Women with persistent bleeding despite treatment

• Hysteroscopy: A thin telescope is passed through the cervix into the uterine cavity under direct visualization. This is the gold standard for diagnosing intrauterine pathology (polyps, submucosal fibroids, endometrial abnormalities) and allows simultaneous biopsy or treatment. It is performed either as an outpatient procedure (office hysteroscopy) or under general anesthesia.

---

Treatment

The treatment of metrorrhagia is entirely dependent on the underlying cause. There is no single universal treatment. Instead, the approach must be tailored to each individual based on several key factors: the specific diagnosis, the woman’s age, her reproductive plans, her general health, and her personal preferences.

The following is an overview of the main treatment options available.

1. Hormonal Contraceptives (for Anovulatory Bleeding and Endometrial Stabilization)

The combined oral contraceptive pill (COCP) is one of the most widely used treatments for metrorrhagia not caused by structural pathology. By providing a consistent, predictable level of estrogen and progestogen, it:

• Suppresses the erratic hormonal fluctuations that cause anovulatory bleeding
• Stabilizes the endometrium, preventing excessive proliferation
• Produces a predictable, regular, and usually lighter withdrawal bleed during the pill-free week

Alternative delivery methods with similar efficacy include:

• The vaginal ring, also known as NuvaRing, is used on a monthly cycle
• The contraceptive patch is applied weekly
• The levonorgestrel-releasing IUS (Mirena) is highly effective at reducing or eliminating bleeding. It is the preferred option for many women with anovulatory bleeding and menorrhagia, as it also provides contraception for 5 years.

Progestogen-only regimens (such as cyclical norethisterone or medroxyprogesterone acetate) can be used when estrogen is contraindicated (e.g., in women over 35 who smoke, or those with a history of venous thromboembolism). They provide progesterone opposition to endogenous estrogen, stabilizing the endometrium and reducing anovulatory bleeding.

2. GnRH Analogues (Gonadotropin-Releasing Hormone Agonists)

GnRH agonists (such as leuprolide, goserelin, nafarelin, or buserelin) first stimulate pituitary gonadotropin secretion. However, with continuous use, they eventually cause profound suppression of this secretion. The result is a state of “medical menopause”, with very low estrogen levels, cessation of ovulation, and amenorrhea (absence of periods).

GnRH agonists are highly effective at stopping heavy or persistent uterine bleeding and reducing the size of uterine fibroids. However, they are only suitable for short-term use, typically lasting 3 to 6 months, because of significant side effects. These include menopausal symptoms like hot flushes, vaginal dryness, and mood changes, as well as bone density loss with prolonged use.

They are most commonly used:

• As bridge therapy before surgery (to shrink fibroids and reduce operative blood loss)
• When rapid, temporary suppression of bleeding is needed

Add-back therapy, which involves the concurrent administration of low-dose estrogen and progesterone, can mitigate menopausal side effects while preserving the beneficial effect on bleeding. This approach allows for somewhat longer treatment courses.

3. Tranexamic Acid (Antifibrinolytic Therapy)

Tranexamic acid is a non-hormonal antihemorrhagic medication that works by inhibiting the breakdown of blood clots (fibrinolysis). By stabilizing clots that form at the endometrial surface, it reduces the volume of uterine bleeding. This effect is particularly useful during episodes of acute heavy bleeding.

Key characteristics:

• Non-hormonal: Does not affect ovulation or fertility
• Taken only during the days of heaviest bleeding (typically 3–5 days)
• Reduces menstrual blood loss by approximately 30–60%
• Also effective for intermenstrual bleeding episodes
• Generally well tolerated; main side effects are nausea and gastrointestinal discomfort
• Not appropriate for women with a personal history of venous thromboembolism without specialist advice

4. NSAIDs and Pain Management

Non-steroidal anti-inflammatory drugs (NSAIDs) such as ibuprofen and mefenamic acid have a modest effect on reducing uterine bleeding (by inhibiting prostaglandin synthesis) and are more valuable for their analgesic and anti-inflammatory effects in managing associated pelvic pain and dysmenorrhea. They are often used in combination with other treatments rather than as a standalone therapy for metrorrhagia.

5. Iron Supplementation

When iron-deficiency anemia is present as a complication of recurrent intermenstrual bleeding, oral iron supplementation is essential:

• Oral iron: Ferrous sulfate, ferrous fumarate, or ferrous gluconate. These can be taken daily or every other day. Alternate-day dosing may improve absorption and reduce gastrointestinal side effects.
• Intravenous iron infusion: For women with severe anemia, inability to tolerate oral iron, or malabsorption.
• Dietary modifications: Increasing consumption of iron-rich foods (red meat, lentils, spinach, fortified cereals) and pairing them with vitamin C to enhance absorption.

Iron supplementation corrects the anemia, but it does not address the underlying bleeding. Both aspects of treatment must be pursued at the same time.

6. Treating the Underlying Cause

When metrorrhagia results from a specific identifiable cause, targeted treatment of that cause is fundamental:

• Pelvic infections: Appropriate antibiotic therapy based on the identified pathogen (e.g., doxycycline + metronidazole for chlamydia-related PID; ceftriaxone + doxycycline for gonorrhea-related disease); sexual partner notification and treatment.
• Uterine polyps: Hysteroscopic polypectomy.
• Cervical polyps: Outpatient removal.
• Fibroids: Medical management (tranexamic acid, GnRH agonists, LNG-IUS) or surgical intervention (hysteroscopic myomectomy, laparoscopic/open myomectomy, uterine fibroid embolization) depending on size, location, and reproductive plans.
• Thyroid disease: Thyroid hormone replacement (hypothyroidism) or antithyroid therapy (hyperthyroidism).
• PCOS: Weight management, hormonal contraception, metformin (for insulin resistance).
• Endometrial cancer: Multidisciplinary oncological management typically involves surgery, such as hysterectomy with bilateral salpingo-oophorectomy, along with radiation and/or chemotherapy. The specific treatment plan depends on the stage of the cancer.
• Cervical cancer: Treatment varies by stage. Options range from local excision, such as LLETZ or cone biopsy for precancerous lesions, to radical surgery and chemoradiotherapy for invasive cancer.
• Coagulation disorders: Specialist hematological management; desmopressin for von Willebrand disease; hormone therapy to reduce menstrual bleeding.
• Medication-related bleeding: Review and adjustment of the offending medication where possible.

7. Surgical Treatment

Surgical options are reserved for women in whom:

• Medical management has been ineffective, contraindicated, or not tolerated
• There is a specific structural abnormality best addressed surgically
• Future pregnancy is not desired (for definitive procedures)

Endometrial ablation: A minimally invasive procedure that destroys the endometrial lining using heat, microwave energy, or radiofrequency. Highly effective at reducing or eliminating menstrual and intermenstrual bleeding. Not suitable for women who wish to conceive. Performed as a day-case procedure with rapid recovery.

Hysterectomy: Surgical removal of the uterus offers a definitive and permanent solution for uterine bleeding, regardless of the cause. Guarantees complete and permanent cessation of all menstrual and intermenstrual bleeding. Reserved for women with completed family planning in whom all other options have failed or are contraindicated. Does not cause menopause unless the ovaries are also removed.

Can be performed vaginally, laparoscopically (minimally invasive), or via open laparotomy, depending on the indication and surgical expertise available.

---

Key Takeaways

• Metrorrhagia is significant uterine bleeding occurring unexpectedly between two menstrual periods; it differs from spotting (minimal intermenstrual bleeding) and menorrhagia (heavy bleeding during periods).
• The most common causes include hormonal contraceptives, pelvic infections, anovulatory cycles, uterine polyps, and fibroids. Most of these conditions are benign and treatable.
• Anovulatory cycles, where ovulation does not occur, account for approximately 90% of dysfunctional uterine bleeding. They are particularly common in adolescents and perimenopausal women.
• Any postmenopausal bleeding must be investigated urgently to exclude endometrial cancer.
• Iron-deficiency anemia is the principal direct complication of recurrent intermenstrual bleeding and should be screened for and treated.
• Diagnosis involves a structured approach: clinical history, pelvic examination, blood tests (hormonal, iron studies, STI screen, pregnancy test), and imaging (transvaginal ultrasound as first-line).
• Treatment is entirely dependent on the underlying cause and may include hormonal therapies, tranexamic acid, antibiotics, treatment of systemic disease, or surgical intervention.
• Women should never hesitate to seek gynecological evaluation for unexplained or recurrent intermenstrual bleeding. Early diagnosis and treatment lead to better outcomes and greater peace of mind.

---

References and Bibliography

• NHS: What causes bleeding between periods?
• Mayo Clinic Health System: Heavy or Irregular Bleeding
• National Institute for Health and Care Excellence (NICE). Heavy menstrual bleeding: assessment and management. NICE guideline NG88. Updated 2021. Available at: https://www.nice.org.uk/guidance/ng88
• Munro MG, Critchley HO, Fraser IS; FIGO Menstrual Disorders Committee. The two FIGO systems for normal and abnormal uterine bleeding symptoms and classification of causes of abnormal uterine bleeding in the reproductive years: 2018 revisions. International Journal of Gynaecology & Obstetrics. 2018;143(3):393–408.
• American College of Obstetricians and Gynecologists (ACOG). Practice Bulletin No. 128: Diagnosis of Abnormal Uterine Bleeding in Reproductive-Aged Women. Obstetrics & Gynecology. 2012;120(1):197–206.
• James AH. Women and bleeding disorders. Haemophilia. 2010;16 Suppl 5:160–167.
• Hickey M, Higham JM, Fraser I. Progestogens with or without oestrogen for irregular uterine bleeding associated with anovulation. Cochrane Database of Systematic Reviews. 2012.
• Goldstein SR. The role of transvaginal ultrasound or endometrial biopsy in the evaluation of the menopausal endometrium. Gynecologic Oncology. 2010;116(3):385–386.
• Bofill Rodriguez M, Lethaby A, Low C, Cameron IT. Cyclical progestogens for heavy menstrual bleeding. Cochrane Database of Systematic Reviews. 2019.